News for Fulcrum Therapeutics, Inc. (FULC)

Published at

Feb 26, 2025 3:02 PM

by rttnews.com

mixed

mixed

Pre-market Movers: ENVB, TRNR, FLYW, GO, EYE…

Florida-based Enveric Biosciences, Inc. (ENVB) is up over 155 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

EYE ENVB COMM ZI SVT SMCI PRCHW PRCH LMND.MX LMND GO FULC AVNS 0A91.L

Read more →
Published at

Feb 26, 2025 8:04 AM

by gurufocus.com

neutral

neutral

Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Resilience

Year-End Cash Position: $241 million.Q4 2024 Collaboration Revenue: $0 compared to $900,000 in Q4 2023.Q4 2024 Research and Development Expenses: $11.7 million

FULC

Read more →
Published at

Feb 26, 2025 6:06 AM

by gurufocus.com

neutral

neutral

Q4 2024 Fulcrum Therapeutics Inc Earnings Call Transcript

Feb 25, 2025 / 01:00PM GMTOperator Good morning and welcome to Fulcrum Therapeutic 4th quarter and full year 2024 financial results and business update conferen

FULC

Read more →
Published at

Feb 25, 2025 2:00 PM

by gurufocus.com

positive

positive

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

”• On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by th

FULC

Read more →
Published at

Feb 25, 2025 7:52 AM

by gurufocus.com

positive

positive

Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result

Fulcrum Therapeutics Inc (FULC) is set to release its Q4 2024 earnings on Feb 25, 2025. The consensus estimate for Q4 2024 revenue is $7.03 million, and the ear

FULC

Read more →
Published at

Feb 18, 2025 11:00 PM

by gurufocus.com

positive

positive

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the ”Company”) ( FULC), a clinical-stage biopharmaceutical company focus

FULC

Read more →
Published at

Feb 18, 2025 1:29 PM

by rttnews.com

mixed

mixed

Pre-market Movers: EFOI, INLF, TNMG, LVWR, PGY…

Ohio-based Energy Focus, Inc. (EFOI) is up over 63 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

MBRX IDAID IDAI FULC EFSI EFOI EEX EDSA AIID.IR PCTTW PCTTU PCT PALI OSCR HEES BGI

Read more →
Published at

Feb 7, 2025 11:59 PM

by seekingalpha.com

positive

positive

Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks. Click to find out why FULC is a Hold.

FULC

Read more →
Published at

Feb 7, 2025 10:53 PM

by manilatimes.net

positive

positive

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

**media[535345]**

FULC

Read more →
Published at

Feb 6, 2025 11:00 PM

by gurufocus.com

positive

positive

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the ”Company”) ( FULC), a clinical-stage biopharmaceutical company focus

FULC

Read more →
Published at

Jan 10, 2025 1:12 PM

by manilatimes.net

mixed

mixed

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

**media[511560]**

SPRO LRMR FULC

Read more →
Published at

Jan 7, 2025 1:01 AM

by gurufocus.com

positive

positive

Suvretta Capital Management, LLC Acquires Additional Shares in Fulcrum Therapeutics Inc

On December 27, 2024, Suvretta Capital Management, LLC made a significant move by acquiring an additional 2,221,821 shares of Fulcrum Therapeutics Inc (FULC). T

KURA ITCI FULC

Read more →
Published at

Dec 7, 2024 1:07 AM

by gurufocus.com

positive

positive

BlackRock, Inc. Reduces Stake in Fulcrum Therapeutics Inc.

On November 30, 2024, BlackRock, Inc. (Trades, Portfolio) executed a strategic transaction involving Fulcrum Therapeutics Inc. The firm reduced its holdings by

NVDAD.BA NVDAC.BA NVDA.MI MSFTD.BA MSFTCL.SN MSFTC.BA MSFTB.BA MSFT.MI FULC BLQA.DE BLK.MX BLK APC.DE AMZNCL.SN AMZN.SN AMZN.MX AMZN AMZ.DE AAPLD.BA AAPLCL.SN AAPLC.BA AAPL.SN AAPL.NE AAPL.MX AAPL.BA AAPL 0QZZ.L

Read more →
Published at

Nov 28, 2024 6:00 PM

by zacks.com

neutral

neutral

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why

Fulcrum Therapeutics (FULC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FULC

Read more →
Published at

Nov 26, 2024 11:00 PM

by gurufocus.com

positive

positive

Fulcrum Therapeutics to Participate in Upcoming December Conferences

CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the ”Company”) ( FULC), a clinical-stage biopharmaceutical company focus

FULC

Read more →
Published at

Nov 19, 2024 6:02 PM

by investing.com

neutral

neutral

Fulcrum Therapeutics stock hits 52-week low at $2.87 By Investing.com

Fulcrum Therapeutics stock hits 52-week low at $2.87

FULC

Read more →
Published at

Nov 14, 2024 1:48 AM

by seekingalpha.com

positive

positive

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ETCompany ParticipantsAlex Sapir - President and Chief...

FULC

Read more →
Published at

Nov 13, 2024 1:21 PM

by manilatimes.net

positive

positive

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

**media[464672]**

MYOK FULC

Read more →
Published at

Nov 13, 2024 1:21 PM

by seekingalpha.com

neutral

neutral

Fulcrum Therapeutics GAAP EPS of -$0.35 beats by $0.05 (NASDAQ:FULC)

Fulcrum Therapeutics press release (FULC): Q3 GAAP EPS of -$0.35 beats by $0.05. Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents,

FULC

Read more →
Published at

Oct 11, 2024 10:30 PM

by benzinga.com

positive

positive

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Fulcrum Therapeutics (NASDAQ:FULC)

CAMBRIDGE, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with

FULC

Read more →